KissPeptin 10
Buy 2 Or More Products Get Free 3ML BAC Water!
Kisspeptin (also known as metastin) is a naturally occurring neuroendocrine peptide that plays a pivotal role in human reproduction by stimulating gonadotropin-releasing hormone (GnRH) secretion. This small peptide binds to the GPR54 receptor in the hypothalamus, triggering pulsatile GnRH release and downstream secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) Originally identified as a metastasis-suppressor gene product, Kisspeptin has become a major focus in reproductive endocrinology. This educational protocol presents a once-daily subcutaneous approach for research use.
Reconstitution Steps
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Protocol Overview
Concise summary of the once‑daily regimen.
Goal: Support physiological reproductive hormone signaling through upstream GnRH stimulation.
Schedule: Daily subcutaneous injections for 8–12 weeks.
Dose Range: 100–200 mcg daily with gradual titration.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for precise low-volume measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Dosing Protocol
Suggested daily titration approach.
Start: 100 mcg daily for 1–2 weeks to assess sensitivity.
Titrate: Increase to 200 mcg daily if tolerated and necessary.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; avoid prolonged continuous use to prevent tachyphylaxis.
Timing: Any consistent time; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions with desiccant if possible.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable up to ~8 weeks; avoid freeze–thaw.
Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
Use new sterile insulin syringes; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose and site rotation to maintain consistency.
Discard bacteriostatic water after 28 days once opened.
How This Works
Kisspeptin is an upstream trigger for the reproductive hormone cascade. Upon subcutaneous injection, kisspeptin rapidly binds to kisspeptin receptors (GPR54) on GnRH neurons in the hypothalamus, causing immediate release of GnRH. This in turn stimulates the anterior pituitary to secrete LH and FSH, which act on the gonads to boost sex steroid production and support gametogenesis. Importantly, kisspeptin’s action is GnRH-dependent—if GnRH release is blocked, kisspeptin cannot induce LH/FSH secretion. This confirms that kisspeptin works by unlocking the body’s own GnRH stores, providing a more physiologic pattern of hormone release compared to direct GnRH or hCG administration.
Potential Benefits & Applications
Research on kisspeptin has revealed multiple potential benefits for reproductive health.
Physiological Sex Hormone Stimulation: Increases endogenous testosterone and estrogen levels by amplifying the body’s own LH/FSH signals without suppressing the HPG axis.
Fertility Restoration: Shows promise in functional hypothalamic amenorrhea by rekindling GnRH/LH pulsatility and resuming menstrual cycles.
IVF Ovulation Trigger: Can induce robust LH surge to mature oocytes while potentially lowering the risk of ovarian hyperstimulation syndrome compared to traditional hCG triggers.
Safety Profile: Generally well tolerated; occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.
Lifestyle Factors
Complementary strategies for optimal outcomes.
Maintain adequate nutrition and healthy body weight to support endogenous hormone production.
Prioritize sleep and stress management, as these factors significantly impact the HPG axis.
Monitor for changes in reproductive function or hormone-related symptoms.
Consider combining with appropriate lifestyle interventions for conditions of hypothalamic suppression.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources.
Clean the vial stopper and skin with alcohol; allow to dry completely.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (45° for thin individuals, 90° with adequate fat).
Do not aspirate for subcutaneous injections; inject slowly and steadily.
Rotate sites systematically (abdomen at least 2 inches from navel, outer thighs, upper arms, upper buttocks) to avoid tissue irritation.
Use a new sterile syringe for each injection; dispose of used syringes in a proper sharps container.
